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Abstract 
GBO-006 was shown to be a highly specific and selective PLK2 inhibitor that promoted mitotic arrest in 
various cancer cell lines, subsequently resulting in their apoptotic death.  Intraperitoneal alternate day 
dosing of GBO-006 using 100 % DMSO as formulation showed significant tumor regression in xenograft 
models, demonstrating proof of concept of PLK2 inhibition in vivo. These studies necessitated the 
development of a suitable and GRAS (generally considered as safe) preformulation for pharmacokinetic and 
efficacy studies. GBO-006 possesses challenging physicochemical and biopharmaceutical properties like 
poor solubility in aqueous media, low permeability and a crystalline nature. Different methods like 
cosolvency, complexation and micellar solubilization were employed to improve the solubility of GBO-006.  
A strategy of co-solvency is used to solubilize the GBO-006 up to 10 mg/mL. A formulation with 20 % 
DMSO, 40 % PEG 400, 30 % of 100 mM citrate buffer (pH 3.0) and 10 % solutol displayed clear solution 
without any visual precipitation of the drug even after 2 weeks of storage. GBO-006 showed moderate 
clearance in rat and high systemic clearance in mouse and dog. It showed poor oral bioavailability across 
all species. Intraperitoneal dosing of GBO-006 demonstrated the linear exposure. GBO-006 showed 
significant inhibition of tumor progression.   
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Introduction 
The up regulation of Polo like kinase PLK1 plays a key role in mitosis but little is known about the 
oncogenic significance of PLK2 [1-2]. PLK2 kinase activity is essential for centriolar duplication and is also 
believed to play a regulatory role in the survival pathway [3-5]. Protein tyrosine hyper-phosphorylation and 
the up regulation of serine/threonine kinases associated with cell cycle progression have been linked to the 
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etiology of cancer. In our attempt to develop ATP-mimetic compounds that are cytotoxic against a panel of 
cancer cell lines, we identified several sulfonyl pyridopyrimidines that exhibit cyto-toxicity at nanomolar 
concentrations [6-8]. The most potent of these compounds, GBO-006 (2-(1H-indol-5-ylamino)-6-(2,4-
difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one) was found to be a specific PLK2 
inhibitor when profiled against a panel of 288 wild-type, 55 mutant and 12 special kinases. In vitro testing 
revealed that GBO-006 was found to be PLK2 specific and selective inhibitor with nanomolar potency and 
no inhibitory activity against PLK1, PLK3 and PLK4. The cytotoxic effect of the drug is mediated by apoptosis 
as evidenced by the induction of caspase 3/7 activity and by the cleavage of PARP in a dose dependent 
manner [9]. It affects cell cycle progression by blocking tumor cells in the G2/M phase. Intraperitoneal 
alternate day dosing of GBO-006 using 100 % DMSO as formulation lead to significant tumor regression in 
Xenograft models, demonstrating proof of concept of PLK2 inhibition in vivo. However, GBO-006 showed 
poor solubility in aqueous media (<0.1 μg/mL), had a low permeability and a crystalline nature, making it 
very hard to have a feasible formulation with moderate concentration, prompting studies to develop a 
preclinical formulation. In this paper, we have presented the use of co-solvent based formulation to 
increase the solubility of the compound. The developed formulation was subsequently used to perform 
pharmacokinetic studies (mice, rats and dogs) and efficacy studies, with GBO-006 as a single agent in SCID 
Beige mouse xenograft models. 
Materials and methods 
Chemicals and reagents 
GBO-006 was synthesized with the purity of 99.5 % in-house (GVK biosciences Pvt. Ltd, Hyderabad, 
India). All co-solvents, surfactants, solutol, glycerin, complexing agents, lipids and oils were purchased from 
Sigma-Aldrich (St. Louis, USA). Liquid chromatography grade acetonitrile, methanol and ethanol were 
purchased from E. Merck Limited (Mumbai, India). Multi-screen solvinert inert filter plates (0.45 μM, low 
binding hydrophilic PTFE) were purchased from Millipore. All aqueous solutions were prepared in Mili-Q 
water (Millipore, MA). All other chemicals were of analytical grade. Matrigel was procured from Sigma-
Aldrich (DLW356235). 
Solubility studies 
Solubilization approach using co-solvent(s) and surfactant(s) were tried to optimize the best formulation 
for pharmacokinetic and efficacy studies. To estimate solubility qualitatively, known amount of GBO-006 
was taken in clear glass vial. To this, known volume of test media was added and observed for clarity.  GBO-
006 was dissolved in nearly 30-80 % of mixtures of co-solvents with the aid of heating and bath sonication 
as and when required. Aqueous medium was added only if solution was obtained in co-solvents. Aqueous 
medium consisted of solution of anti-nucleating polymer and/or surfactant in distilled water or buffer. If 
required, sample was intermittently bath sonicated and heated at 60-80 °C. Test media was added either till 
a solution was obtained or till theoretical concentration was achieved (data not shown). The final sample 
was observed both visually and also by using polarized light microscopy for better clarity (in terms of 
number of visible particles).  
Pharmacokinetics 
Pharmacokinetics in rats 
Male Sprague Dawley (SD) rats weighing 240-260 g were obtained from the taconic laboratories (Vivo 
biotech, Hyderabad, India). They were housed under standard conditions and were maintained under a 
12 h light/dark cycle in the laboratory animal resources facilities, GVK Biosciences Pvt. Ltd, Hyderabad, India 
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(AAALAC accredited). They were allowed access to commercial rodent chow and water ad libitum. Rats 
were fasted overnight before dosing and then until 3 h after dosing. Water was allowed ad libitum during 
the fasting period. Rats were cannulated at the jugular vein for serial bleeding. Three male rats per group 
were dosed via oral (PO, 5 mg/kg) and intravenous (IV, 1 mg/kg) routes for the determination of 
pharmacokinetics of GBO-006. After dosing, 0.3 ml specimens of blood were collected by serial sampling 
from the jugular cannula at 0.25, 0.5, 1, 2, 4, 8 and 24 h after PO, and 0.08, 0.25, 0.5, 1, 2, 4, 8, 24 h after IV 
route, respectively. After collection, blood was processed to plasma by centrifugation at 10000 rpm for 5 
min, and samples were analyzed by LC-MS/MS. 
Pharmacokinetics in mice 
Swiss albino mice were obtained from taconic Laboratories (Vivo biotech, Hyderabad, India). They were 
housed under standard conditions and were maintained under a 12 h light/dark cycle in the laboratory 
animal resources facilities, GVK Biosciences Pvt. Ltd, Hyderabad, India (AAALAC accredited). They were 
allowed access to commercial rodent chow and water ad libitum. Mice were fasted overnight before dosing 
and then until 3 h after dosing. Water was allowed ad libitum during the fasting period. The bodyweights of 
individual mice, ranging from 25 to 30 g, were determined on the morning of the study. Nine mice for oral 
route and twelve mice for i.v. route were dosed. After dosing, 0.1 ml specimens of blood were collected by 
stagger sampling with two bleeds per mouse from the retro orbital plexus at  0.5, 1, 2, 4, 8, 24 h after PO 
route and 0.08, 0.25, 0.5, 1, 2, 4, 8, 24 h after IV route respectively. After collection, blood was processed to 
plasma by centrifugation at 10000 rpm for 5 min, and samples were analyzed by LC-MS/MS. 
Dose dependent intraperitoneal pharmacokinetics in mice 
GBO-006 was administered in mice via IP route at 10, 30, 75 and 100 mg/kg dose to understand the 
dose dependent exposure. After dosing, 0.3 ml specimens of blood were collected by stagger sampling with 
two bleeds per mouse from the retro orbital plexus at 0.5, 1, 2, 4, 8, 24 h. Blood was processed for plasma 
collection by the process mentioned in the above pharmacokinetics section. 
Pharmacokinetics in dogs 
Dog studies were performed at Palamur Biosciences Pvt. Ltd (Hyderabad, India). Six male Beagle dogs 
were housed under standard conditions and were maintained under a 12 h light/dark cycle in the 
laboratory animal resources facilities. They were allowed access to water ad libitum. Dogs were fasted 
overnight before PO dosing and then until 4 h after dosing. Water was allowed during the fasting period. 
The body weight of the individual dogs ranged from 9.6 to 14.3 kg. Three male dogs per group were dosed 
per oral (PO), intravenous (IV) at 5 and 1 mg/kg for the determination of pharmacokinetics of GBO-006. 
After dosing, 0.3 ml specimens of blood were collected by serial sampling from the  saphenous  vein at 
0.167, 0.5,1, 2, 4, 8, 12, 24 h after PO route and 0.033, 0.167, 0.5,1, 2, 4, 8, 12, 24 h after IV route, 
respectively. After collection, blood was processed to plasma by centrifugation at 10000 rpm for 5 min, and 
samples were analyzed by LC-MS/MS. 
Liquid chromatography - mass spectrometry analysis 
In vivo samples were prepared by protein precipitation with the addition of 200 µL acetonitrile 
containing internal standard (telmisartan; 200ng/mL) to 25 µL sample volume. Samples were vortexed and 
centrifuged at 4000 rpm for 10 min. Then 100 µL of supernatant was diluted with 100 µL of methanol: 
water mixture vortexed and injected for analysis. Standard and quality control samples were prepared by 
adding 1 µL of aqueous known standard / quality control samples to 24 µL of blank plasma and processed 
as mentioned above. The selected [M+H]+ and product ions monitored were m/z 468.2, 290.2 for GBO-006 
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(Figure 1) and m/z 515.3, 276.1 for telmisartan, respectively. The high-performance liquid chromatography 
column was a C18-XBridge column (4.6x50 mm, 3.5 µm) maintained at 400 C with a flow rate of 1.0 mL/min 
with the split ratio of 60:40. The mobile phase consisted of 0.1 % formic acid (A) and methanol (B). The 
initial mobile phase composition was 80% A/20% B and continued until 1.0 min, then it was changed to 5 % 
A/95% B over 2.1 minutes. After 2.1 min, the mobile phase is slowly shifted to 80% A/20% B by 2.2 min   
following which it was held at same for 3.2 minutes. The high performance liquid chromatography (HPLC) 
was interfaced to API 4000 (AB Sciex, CA) mass spectrometer operated in the positive ion electrospray with 
multiple reaction monitoring (MRM) mode. The peak area ratio of analyte to internal standard was plotted 
against analyte concentrations, and the standard curve and was fitted by weighted (1/X2) least-squares 
linear regression in the concentration ranged from 1 to 1000 ng/mL. A correlation of 0.995 was desirable 
for the calibration curve. The limit of quantitation for the purposes of this assay was 1 ng/mL. 
 
Figure 1. LC-MS spectra representing the product ion of GBO-006  
Pharmacokinetic analysis 
The pharmacokinetic parameters were obtained by fitting the plasma concentration-time data to a non-
compartmental model by using Phoenix WinNonlin-v6.3.0.395; (Pharsight, Mountain view, CA). The 
maximum plasma concentration (Cmax) and the time to reach the same (Tmax) were determined by visually 
inspecting the profiles of plasma drug levels versus time. The half-life of plasma drug elimination (t1/2) was 
the ratio of 0.693 to the slope obtained by log-linear regression of the terminal phase of the drug plasma 
profile. The area under the concentration-time curve to terminal time AUC0-t), (area under the 
concentration-time curve to infinite time (AUC0-∞) and the mean residence time (MRT) were also evaluated. 
AUCt was calculated by the linear/log trapezoidal rule. Other pharmacokinetic variables, including the total 
plasma clearance (CL), steady-state volume of distribution (Vss), and oral bioavailability (%F) were also 
calculated. 
Xenograft study 
All animal studies were performed according to the guidelines and approval of the appropriate Animal 
Care Committees. Female SCID beige mice 4–6 weeks of age were purchased from Taconic laboratories 
(Vivo biotech, Hyderabad, India) and housed in a pathogen-free environment under controlled conditions 
 +MS2 (468.30): 40.000 Volts from Sample 2 (TuneSampleID) of GBO-006-Q3.wiff (Turbo Spray), Centroided Max. 6.9e5 cps.
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of light and humidity and allowed free access to food and water. Tumors were developed from MDA-MB-
231 cells inoculated subcutaneously (SC) into each mouse as previously described [10]. MDA-MB-231 cells 
were grown in RPMI 1640 w/ 10 % FBS, 2 % P/S, 1.25 % L-glut, and 1 % sodium pyruvate to 80 % confluency. 
Cells were trypsinized with 0.25 % trypsin for 3-5 minutes, washed and suspended at 100 million cells per 
ml. Animals received 5 million cells in matrigel (1:1 ratio of media and matrigel) and injected 
subcutaneously at the flank. Tumors were measured three times a week with vernier calipers and tumor 
volume measured using the formula length x width 2/2. Treatment was initiated when the tumors reached 
an average volume of 100 mm3. One group was dosed with the formulation {(20 % v/v DMSO + 40 % w/v  
PEG 400 + 10 % w/v  Solutol +  30 % v/v citrate buffer (100mM)}  with the dose volume of 10 ml/kg as a 
vehicle  control, whereas the two other groups were dosed via intraperitoneal route with 30 and 75/mg/kg 
GBO-006. All dosing were done once daily (qd) for 24 days. Animal body weights were taken every alternate 
day, and they were monitored for general health status and any possible signs of treatment related toxicity.  
Results 
Development of formulation of GBO-006 
Various percentage compositions of water soluble organic cosolvents, surfactants were evaluated for an 
optimized GBO-006 formulation (Table 1). GBO-006 concentrations in these formulations were kept fixed at 
10 mg/mL. Among these formulations (#A-K), GBO-006 was initially dissolved and subsequently exhibited 
various degrees of precipitation after 24 h storage at room temperature. However, formulation #L with 
20 % DMSO, 40 % PEG 400, 30 % of 100mM citrate buffer (pH 3.0) and 10 % solutol displayed clear 
solutions without any visual precipitation of the drug even after 2 weeks of storage.  Therefore, this 
formulation was selected for in vivo pharmacokinetic and efficacy studies.   
Table 1. Formulation trails for GBO-006 at 10 mg/mL by solvation strategy using co-solvents and surfactants 
Formula Vehicle composition Appearance at CRT 
A 
20% v/v NMP + 20% v/v Ethanol + 20% v/v PEG 400 + 10% w/v TPGS + 1% w/v Poloxamer 
188 + purified water q.s. 
Precipitation after 8h 
B 
20% v/v NMP + 20% w/v Glycerin+ 20% v/v PEG 400 +10% w/v solutol Hs 15 + 10% w/v 
poloxamer 188 +purified water q.s. 
Precipitation after 48h 
C 
20% v/v NMP + 20% v/v Ethanol+ 20% v/v PEG 400 +10% w/v solutol Hs 15 + 10% w/v 
TPGS + purified water q.s. 
Precipitation after 48h 
D 
20% v/v NMP + 20% w/v Glycerin+ 20% v/v Ethanol +10% w/v TPGS + 10% w/v Poloxamer 
188 + purified water q.s. 
Precipitation after 12h 
F 
20% v/v NMP + 10% v/v DMSO + 30% v/v PEG 400 + 20% w/v Cremophor EL + + Purified 
water q.s 
Precipitation after 24h 
G 
20% v/v NMP + 10% v/v DMSO + 30% v/v PEG 400 + 10% w/v Solutol HS 15 + + Purified 
water q.s 
Precipitation after 48h 
H 20% v/v NMP + 10% v/v DMSO + 30% v/v PEG 400 + 20% w/v TPGS + Purified water q.s Precipitation after 48h 
I 
20% v/v NMP + 10% v/v DMSO + 30% v/v PEG 400 + 20% w/v Poloxamer 188 + Purified 
water q.s 
Precipitation after 48h 
J 20% v/v NMP + 20% v/v DMSO + 30% v/v PEG 400 + 20% v/v Labrasol + Purified water q.s Precipitation after 72 h 
K 20% v/v DMSO + 30% w/v  PEG 400 + 10% w/v  Solutol +  30 % v/v citrate buffer (100mM) 
Precipitation after 1 
week 
L 20% v/v DMSO + 40% w/v  PEG 400 + 10% w/v  Solutol +  30 % v/v citrate buffer (100mM) 
No visual precipitation up 
to 2 weeks 
We observed that the solubility of GBO-006 in DMSO, a pharmaceutically acceptable strong solubilizing 
agent, was quite high. Hence, DMSO was chosen as the solubilizing agent in our formulation. The PEG 400 
(at 40 % v/v) was found to be a suitable additive in the formulation, as we observed a clear solution of high 
miscibility and compatibility with water. However, at a lower concentration of 10-30 % v/v, PEG 400 was 
found to be insufficient to prevent precipitation of free GBO-006, observed after 24 h. Therefore, PEG 400 
was fixed at a concentration of 40 % v/v. 
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Among the different percentage compositions of the nonionic surfactants considered, including Tween 
80, cremophor, labrasol, transcutol and solutol, the latter surfactant was picked as an ingredient in the 
optimal formulation at a concentration of 10 % w/v. This was purely based on the solubility, clarity and 
miscibility of solutol at this concentration with the rest of the additives in the formulation. It was also found 
that a percentage concentration of 5 % w/v is insufficient to prevent the precipitation of the free GBO-006. 
Hence, we decided to optimize the formulation with at a percentage concentration of 10 % w/v. 
LC-MS/MS analytical method   
No interfering peaks were observed in blank plasma chromatograms at GBO-006 retention time (Figure 
2). The retention times for GBO-006 and internal standard were 1.58 and 1.80 min, respectively. The 
calibration curves and linearity was determined using weighted (1/x2) linear regression analysis in the 
following ranges of 1 to 1000 ng/mL in rat, mouse and dog plasma. The correlation coefficients were > 
0.995 for calibration curves. The batch was accepted once the low, medium and high quality control (QC) 
samples and standard samples met the acceptance criteria.    
Pharmacokinetics in rats 
A plasma concentration and time profile of GBO-006 obtained is shown in Figure 3 and corresponding 
pharmacokinetic parameters are shown in Table 2. After intravenous bolus injection, the plasma 
concentrations declined by 99 % over the first 4h. GBO-006 showed moderate clearance (equivalent to 
55 % of rat hepatic blood flow) with half-life of 0.6 h and extra vascular distribution. It showed poor oral 
bioavailability. 
Pharmacokinetics in mice 
Following IV and PO administration in mouse, GBO-006 showed high clearance (77 ml/min/kg, 
equivalent to 85 % of mouse hepatic blood flow), short terminal half-life (0.5 h) and poor oral bioavailability 
(Table 3). Similar to rat, after intravenous bolus injection the plasma concentrations declined by 99 % over 
the first 4 h (Figure 4). Dose dependent pharmacokinetic parameters following IP administration at three 
different dose levels are listed in Table 4. As the dose increased from 1 to 3, 7.5 and 10 fold, the area under 
the curve of plasma concentration versus time profile increased 1 to, 5, 8 and 10 fold. As demonstrated in 








Figure 2. Representative MRM chromatograms of GBO-006 obtained from blank plasma sample (A) and 
calibration standard plasma sample of 1 ng/mL, LLOQ (B). 
 
Figure 3. Mean plasma concentration vs. time curve of GBO-006 following its intravenous and oral 
administration in male sprague dawley rat. Each point (n=3) represents the mean ± SD. 
 
Sample Name: "BL"    Sample ID: ""    File: "001.wiff"
Peak Name: "GBO-0061"    Mass(es): "468.200/290.200 Da"
Comment: ""    Annotation: ""
Sample Index:       3     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:    0.00    ng/mL  
Acq. Date:       12/2/2016  
Acq. Time:       1:14:50 PM  
 
Modified:           No    










































































Sample Name: "BL"    Sample ID: ""    File: "001.wiff"
Peak Name: "TELMISARTAN(IS)"    Mass(es): "515.400/276.100 Da"
Comment: ""    Annotation: ""
Sample Index:       3     
Sample Type:     Unknown  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       12/2/2016  
Acq. Time:       1:14:50 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:   20.00   cps
Area Threshold:  100.00   cps
,Num. Smooths:       4     
Sep. Width:         0.20  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.78   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     1.82   min
Area:          413742   counts
Height:         1.32e+005  cps
Start Time:         1.73   min
End Time:           2.01   min




































Sample Name: "GBO-006-STD1"    Sample ID: ""    File: "001.wiff"
Peak Name: "GBO-0061"    Mass(es): "468.200/290.200 Da"
Comment: ""    Annotation: ""
Sample Index:       5     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:    0.00    ng/mL  
Acq. Date:       12/2/2016  
Acq. Time:       1:23:22 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:   20.00   cps
Area Threshold:  100.00   cps
,Num. Smooths:      10     
Sep. Width:         0.20  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.57   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     1.58   min
Area:            2771   counts
Height:         7.91e+002  cps
Start Time:         1.51   min
End Time:           1.66   min


















































Sample Name: "GBO-006-STD1"    Sample ID: ""    File: "001.wiff"
Peak Name: "TELMISARTAN(IS)"    Mass(es): "515.400/276.100 Da"
Comment: ""    Annotation: ""
Sample Index:       5     
Sample Type:     Unknown  
Concentration:      1.00    ng/mL  
Calculated Conc:    N/A            
Acq. Date:       12/2/2016  
Acq. Time:       1:23:22 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:   20.00   cps
Area Threshold:  100.00   cps
,Num. Smooths:       4     
Sep. Width:         0.20  
Sep. Height:        1.00  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.78   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     1.80   min
Area:          639887   counts
Height:         2.05e+005  cps
Start Time:         1.69   min
End Time:           2.07   min
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Table 2. Pharmacokinetic parameters of GBO-006 following its intravenous 
and oral route administration in male Sprague Dawley rat. Data are expressed 
as mean ± SD in three rats.  
 IV PO 
Dose (mg/kg) 1 5 
Cmax (ng/mL) - 22 
Tmax(h) - 1 
AUC0-24h (ng h /mL) 535 87 
DNAUC 535 17 
CL (mL/min/Kg) 30 - 
thalf (h) 0.6 - 
Vdss (L/kg) 1.5 - 
MRT last (h) 0.5 - 
Bioavailability (%F) - 3 
 
Figure 4. Mean plasma concentration vs. time following intravenous and oral administration of GBO-006 in 
male swiss albino mice. 
Table 3.  Pharmacokinetic parameters of GBO-006 following its intravenous and 
oral route of administration in mouse. 
 IV PO 
Dose (mg/kg) 2 5 
CL (mL/min/Kg) 77 - 
thalf (h) 0.5 - 
Vdss (L/kg) 1.7 - 
MRT last (h) 0.4 - 
Cmax, PO (ng/mL) - 64 
Tmax, PO (h) - 0.25 
AUC0-24h (ng h /mL), IV/PO 431 25 
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Table 4. Pharmacokinetic parameters of GBO-006 following intraperitoneal administration 
in swiss albino mouse at 10, 30, 75, 100 mg/kg 
Dose (mg/kg) 10 30 75 100 
Formulation strength  
(mg/mL) 
1 3 7.5 10 
           Cmax (ng/mL) 952 1413 1354 1652 
Tmax (h) 0.25 4 0.25 8 
AUC0-24h, (ng/mL h) 2451 13530 20177 25592 
AUC0-∞(ng/mL h) 2531 13807 27067 33744 
Dose normalized 
AUC0-∞ (ng /mL h) 
253 460 360 337 
 
 
Figure 5. Mean plasma concentration vs. time following intraperitoneal administration of GBO-006 at 
different doses in swiss albino mice. 
Pharmacokinetics in dogs 
A plasma concentration and time profile of GBO-006 obtained in dog is shown in Figure 6 and 
corresponding pharmacokinetic parameters are shown in Table 5. Similar to results in mice, GBO-006 
showed high clearance (47 ml/min/kg, more than dog hepatic blood flow) and short plasma elimination 
half-life (0.7 h) in dogs indicating that the compound is rapidly eliminated from the body. The volume of 
distribution of 2.4 L/kg provides significant distribution into extra vascular space. Poor bioavailability (6 %) 

























100 mg/kg 10 mg/kg
30 mg/kg 75mg/kg
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Figure 6. Mean plasma concentration vs. time following intravenous and oral administration of GBO-006 in 
male beagle dog. Each point (n=3) represents the mean±SD. 
 
Table 5. Pharmacokinetic parameters of GBO-006 following its intravenous and 
oral route administration in beagle dog. Data are expressed as mean ± SD in 
three dogs. 
 IV PO 
Dose (mg/kg) 1 5 
CL (mL/min/Kg) 47 - 
thalf (h) 0.7 - 
Vdss (L/kg) 2.4 - 
MRT last (h) 0.8 - 
Cmax, PO (ng/mL) - 70 
Tmax, PO (h) - 0.8 
AUC0-24h (ng h /mL),  440 160 
Bioavailability (%F) 6 
Xenograft model 
GBO-006 reduced tumor volume by 52 and 58 % at doses of 30 and 75 mg/kg respectively (Figure 7).  
The tumor growth inhibition at 30 mg/kg and 75 mg/kg dose was almost similar. The lack of dose 
dependent efficacy was not known at this movement. No statistically significant weight loss was found 
upon completion of the experiment in the treated groups compared to the vehicle group. There were no 
abnormalities found in liver, heart, lungs and kidneys suggesting that the compound was well tolerated up 
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Figure 7. SCID mice bearing established tumors (100 mm
3
) from MDA-MB-231 cells were treated with GBO-
006 at 30 mg/kg (triangle), 75 mg/kg (Square), or vehicle (circle) for approximately 24 days. Serial tumor 
volumes (mm
3
) were measured at the indicated days. Each data point represents the mean tumor volume of 
8 tumors. 
Discussion 
GBO-006 is a small PLK2 selective kinase inhibitor which showed cytotoxicity against the entire panel of 
16 tumor cell lines, with little or no cytotoxicity towards normal cells. Kinase inhibition assays against a 
panel of 285 kinases revealed that this compound had a remarkable specificity towards PLK2/Snk, a kinase 
involved in centrosome duplication and mitotic progression [11-13]. Most importantly, PLK2 has recently 
been implicated as one of the kinases that links cellular metabolism to cell cycle. Mitochondrial dysfunction 
with increased dependence on glycolysis is frequently observed in cancer cells (known as the Warburg 
effect) and identification of pathways that promote cell survival under conditions of mitochondrial 
dysfunction has therapeutic implications [14]. Intraperitoneal alternate day dosing of GBO-006 using 100 % 
DMSO as formulation caused significant tumor regression in xenograft models, demonstrating proof of 
concept of PLK2 inhibition in vivo. These studies necessitated the need to develop a formulation for 
pharmacokinetic and efficacy studies. The present communication describes the development of preclinical 
formulation to characterize the pharmacokinetic properties and efficacy of GBO-006 in xenograft models to 
determine the degree of inhibition of PLK2 that is required for inhibition of tumor growth and assess how 
concentrations are related to antitumor activity of the compound and to evaluate the validity of using 
PBMN as surrogates. 
GBO-006 possesses challenging physicochemical and biopharmaceutical properties like poor solubility in 
aqueous media, low permeability and a crystalline nature. The poor solubility of GBO-006 in non-aqueous 
media including lipids & oils, limited any further usage of lipid-based technologies. GBO-006 was found to 
melt with degradation at very high temperatures (~346 °C), which limited the usage of any amorphous 
based strategies. In order to understand the solubility, initial screening was conducted in different 
concentrations and combinations of cosolvents and surfactants. Among the various combinations and 
various solvent compositions tried in our laboratory, a cosolvent system was chosen consisting of DMSO, 
PEG 400, solutol and 100 mM citrate buffer at 20:40:10:30 (v/v/v/v) ratios. This system showed 10 mg/mL 
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vivo pharmacokinetic and efficacy evaluations. 
 DMSO and PEG 400 are the major pharmaceutical cosolvents with strong solubilizing properties and 
widely used in oral and parenteral formulations. DMSO is a water miscible polar aprotic solvent with high 
interfacial activity as a drug solubilizer and a penetration enhancer [15]. It also belongs to the class of 
dipolar aprotic solvents which includes dimethylformamide and dimethylacetamide. The cosolvent 
approach is based on the fact that low aqueous solubility of drugs is due to great difference in polarity of 
the two components. Thus when a cosolvent having a polarity value less than that of water is added, the 
polarity difference between the drug and the water-co solvent system reduces thereby increase the 
solubility of drug [16]. 
GBO-006 pharmacokinetic studies provided an overview of the absorption and disposition behavior in 
animal models. GBO-006 showed very poor oral bioavailability (2-6 %) across mice, rats and dogs (Figures 3, 
4 and 6). Potential causes for the low oral bioavailability could be due to metabolism in the gut wall, and 
first-pass metabolism in the liver [17-19]. Following intravenous dosing to mice, rats and dogs, GBO-006 is 
rapidly eliminated from plasma within the first several hours with half-life estimates ranging from 0.5 to 0.7 
h over this period. Overall, GBO-006 pharmacokinetics was comparable across the three species tested. 
Clearance, the critical connection between the administered dose and drug exposure (AUC), was very high 
(which is more than hepatic blood volume) and consistent among mouse and dog. Single day dose 
escalation study by intraperitoneal route demonstrated the dose proportional increase in AUC and Cmax, 
thus displaying linear pharmacokinetics. Since linear exposure was observed in mice, 30 and 75 mg/kg were 
selected for xenograft study, where 30 mg/kg dose showed greater than 50 % tumor regression. Further 
studies are required to compare the efficacy dosage in mice to adverse dosage effects in rat, for non-clinical 
risk assessment. Current efforts are focusing on formulation studies that would enable us to carry out GLP 
tox at higher doses of GBO-006. 
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DMSO  Dimethyl sulfoxide 
DMA  N, N-Dimethyl acetamide 
LLOQ  Lower limit of quantitation 
NMP  N-methyl pyrrolidine 
PBMN  Peripheral blood mononuclear cells  
PEG   Polyethylene glycol 
TPGS D  Alpha tocopheryl polyethylene glycol 1000 succinate 
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